| Ranbaxy Laboratories (BSE: 500359 | NSE: RANBAXY | ISIN: INE015A01028) |
 |
510.70  16.25 (3.29%) |
| BSE : May 16, 16:00 |
|
| 510.80 16.10 (3.25%) |
| NSE : May 16, 15:57 |
|
| Open |
497.00 |
Vol |
762,351 |
| Prev. Close |
494.45 |
|
|
|
Intraday |
52 Week |
|
| Highs |
513.65 |
 513.65 |
|
| Lows |
494.00 |
299.90 |
|
|
| Open |
490.00 |
Vol |
1,844,085 |
| Prev. Close |
494.70 |
|
|
|
Intraday |
52 Week |
|
| Highs |
514.00 |
514.00 |
|
| Lows |
490.00 |
297.05 |
|
|
|
BID |
OFFER |
| Price |
508.10 |
510.45 |
| Quantity |
25.00 |
99.00 |
|
|
BID |
OFFER |
| Price |
0.00 |
510.80 |
| Quantity |
0.00 |
8,160.00 |
|
| Mkt Cap |
19,056.96 |
| |
* P/E |
31.18 |
| |
Div |
170.00 |
| |
* EPS (TTM) |
16.38 |
| |
B/V: |
67.99 |
| Mkt Lot |
1.00 |
| |
FV |
5.00 |
| |
* EPS: As per stand alone adjusted profit after extra-ordinary items |
|
| Historic Prices & Returns of Ranbaxy Labs |
Compare Price Performance With Peers |
| Price |
1 week |
2 week |
1 month |
3 month |
6 month |
9 month |
1 year |
| BSE |
/ |
NSE |
| 470.05 |
480.05 |
481.80 |
396.15 |
423.65 |
360.85 |
395.15 |
| 8.65% |
6.38% |
6% |
28.92% |
20.55% |
41.53% |
29.24% |
| 469.95 |
479.75 |
481.80 |
396.75 |
424.20 |
360.85 |
395.40 |
| 8.69% |
6.47% |
6.02% |
28.75% |
20.41% |
41.55% |
29.19% |
|
Gain/Loss |
|
|
|
| This page Auto Refreshes every 5 minutes |
|
|
|
| |
|
|
|
|
|
| BSE/NSE Notices - Ranbaxy Labs |
| Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 12, 2008, titled "Ranbaxy & Merck Sign Anti-Infective Drug Disc |
| |
| more... |
| |
|
|
|
| Financials of Ranbaxy Labs |
Quarterly |
Annual
|
| Income Statement |
(Mar '08) |
(Dec '07) |
| Net Sales |
987.29 |
4293.02 |
| Other Income |
87.68 |
551.13 |
| PBDIT |
100.28 |
965.72 |
| Net Profit |
103.42 |
617.72 |
|
|
|
| Balance Sheet |
| Total Share Capital |
186.54 |
| Net Worth |
2538.40 |
| Total Debt |
3503.03 |
| Net Block |
1469.52 |
| Investments |
3237.55 |
| Net Current Assets |
1006.93 |
| Total Assets |
6041.42 |
|
|
|
|
|
|
|
|
|
| Company Facts - Ranbaxy Labs |
|
|
|
| Registrars |
Alankit Assignment Ltd.
2E/8, Blazeflash House,
R T A Division, 1st Floor
Jhandewalan Extension,
|
| Tel : 51540060, 51540061, 51540062, 51540063 |
| Fax : 51540064 |
| Email : nahar@alankit.com |
Website :
|
|
|
|
|
|
| Management - Ranbaxy Labs |
| |
| Harpal Singh Non Executive Chairman |
| Vivek Bharat Ram Director |
| Gurcharan Das Director |
| Sunil Godhwani Director |
| P S Joshi Director |
| Nimesh N Kampani Director |
| V K Kaul Director |
| Vivek Mehra Director |
| Ravi Mehrotra Director |
| Shivinder Mohan Singh Director |
| Surendra Daulet-Singh Director |
| Brian W Tempest Non Executive Director |
| Malvinder Mohan Singh Managing Director & CEO |
| Atul Sobti Whole Time Director & COO |
| Ramesh L Adige Whole Time Director |
| |
|
|
Online
